GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Change In Receivables

Amplia Therapeutics (ASX:ATX) Change In Receivables : A$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Change In Receivables?

Amplia Therapeutics's change in receivables for the quarter that ended in Sep. 2024 was A$0.00 Mil. It means Amplia Therapeutics's Accounts Receivable stayed the same from Mar. 2024 to Sep. 2024 .

Amplia Therapeutics's change in receivables for the fiscal year that ended in Mar. 2024 was A$0.00 Mil. It means Amplia Therapeutics's Accounts Receivable stayed the same from Mar. 2023 to Mar. 2024 .

Amplia Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2024 was A$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Amplia Therapeutics's liquidation value for the six months ended in Sep. 2024 was A$3.13 Mil.


Amplia Therapeutics Change In Receivables Historical Data

The historical data trend for Amplia Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Change In Receivables Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amplia Therapeutics Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Amplia Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (ASX:ATX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Amplia Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

2. In Ben Graham's calculation of liquidation value, Amplia Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Amplia Therapeutics's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4.558-1.43+0.75 * 0+0.5 * 0
=3.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics Headlines

No Headlines